Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05877859 · ClinicalTrials.gov registry record
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
A clinical trial of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by Emory University.
- Recruiting
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT05877859 is a study of Breast Cancer Stage II and Breast Cancer Stage III that is actively recruiting participants, run by Emory University. The registered enrollment target is 10 participants, below the 181-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05877859, a study of Breast Cancer Stage II and Breast Cancer Stage III, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is a prospective, single arm, pilot study, designed to evaluate the correlation between the immune and clinical responses of subjects with untreated Stage II-III triple negative breast cancer (TNBC) undergoing standard of care neoadjuvant chemo- immunotherapy.
Conditions Studied
Study Locations (1)
Georgia
- Emory University/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2027-04-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05877859
The ClinicalTrials.gov registry entry for NCT05877859 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (94% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer Stage II appearing as the primary indexed condition, and to 0 interventions.
NCT05877859 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05877859 about?
NCT05877859 is a clinical study titled "Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab". This research study is a prospective, single arm, pilot study, designed to evaluate the correlation between the immune and clinical responses of subjects with untreated Stage II-III triple negative breast cancer (TNBC) undergoing standard of care neoadjuvant chemo- immunotherapy.
What is the current status of trial NCT05877859?
This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2023-05-30. Estimated completion is 2027-04-10.
What conditions does trial NCT05877859 study?
This clinical trial studies the following conditions: Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive, Breast Cancer Triple Negative.
Who is sponsoring clinical trial NCT05877859?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05877859 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Stage II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
RECRUITING · NA
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
RECRUITING · Phase 2
-
Optimizing Surgical Decisions in Young Adults With Breast Cancer
RECRUITING · NA
-
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
RECRUITING · Phase 2
-
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.